Health Care Equipment

Nexalin Tech

Nexalin Tech released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 14.95 K (forecast USD 15 K), actual EPS USD -0.1099 (forecast USD -0.1)

Nexalin Tech released FY2025 annual earnings on March 25 (EST), actual revenue USD 301.65 K (forecast USD 230 K), actual EPS USD -0.5015 (forecast USD -0.49)

Nexalin Tech released FY2025 Q4 earnings on March 25 (EST), actual revenue USD 171.9 K (forecast USD 80 K), actual EPS USD -0.1272 (forecast USD -0.12)

Nexalin Announces Clinical Study on DIFS Technology for ADHD Improvement

Nexalin Releases Investor Presentation on Deep Intracranial Frequency Stimulation Technology

Nexalin Technology Faces Significant Business Risks Due to U.S.-China Trade Tensions

Nexalin Tech released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 18.15 K (forecast USD 40 K), actual EPS USD -0.1279 (forecast USD -0.12)

Nexalin Tech released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 129.75 K and EPS of USD -0.3779

Nexalin Publishes Three Studies on DIFS™ Technology for Alzheimer's Treatment

Nexalin Tech released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 70.59 K (forecast USD 35 K), actual EPS USD -0.1005 (forecast USD -0.14)

Nexalin Tech released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 111.6K, actual EPS USD -0.2457

Nexalin Tech released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 41.02 K (forecast USD 35 K), actual EPS USD -0.1494 (forecast USD -0.1)

Nexalin to Initiate Alzheimer's Clinical Trial

Nexalin Technology issues 3.85 million common shares to raise $5 million

Nexalin Technology Inc. Adjusts Its Offering Plan

Nexalin Submits Gen-2 SYNC System Q-Submission to FDA

Nexalin Technology Secures IRB Approval and Launches Clinical Trials in Brazil

Nexalin Technology Announces HALO Platform Completes Five-Stage Research

Bipartisan Bill Expands Medicare Coverage for AI-Powered Medical Devices

Nexalin Obtains Patent, Advancing Non-Invasive Brain Stimulation for Addiction

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SBIO

LABU

Nexalin Technology Inc. (NXL) has acquired PONM Inc. from GreenLight Ventures for $1.3 million, enhancing its HALO Clarity program with AI-integrated remote patient monitoring and virtual clinic management tools. This acquisition supports Nexalin's pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026. GreenLight Ventures becomes a significant equity holder and strategic partner, aiding in product and regulatory support. Nexalin's stock closed at $0.32, down 5.26%.

nasdaq

iShares US Medical Devices

SPDR S&P Health Equip

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Nasdaq

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial

LABD

Nexalin Technology, Inc. reported a revenue of $14.95K for Q1 2026, down 63.5% from $41.02K a year prior, with a net loss of $2.1M and diluted EPS of ($0.11). The decline in revenue was attributed to lower international equipment sales, although a shift towards higher-margin licensing fees improved gross margins. The company initiated a pivotal insomnia trial and reported increased operating expenses, raising concerns about its financial viability.

TradingView

Direxion S&P Biotech Bear 3X

Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary

Earnings Watch

Nexalin Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 14.95 K

HCWB

AXGN

In Tuesday's pre-market session, several health care stocks experienced significant movements. Notable gainers included Pomdoctor (POM) with a 30.4% rise to $0.39, Omnicell (OMCL) up 23.3% to $46.4, and Axogen (AXGN) increasing by 12.97% to $44.5. Conversely, Soligenix (SNGX) saw a sharp decline of 51.7% to $0.68, while Erasca (ERAS) fell 43.29% to $10.86. Other notable losers included iTonic Holdings (ITOC) down 13.34% and HCW Biologics (HCWB) down 12.62%.

benzinga_article

Pomdoctor

HCW Biologics

Axogen

Erasca

Soligenix

Omnicell

VG Health

Invesco Nasdaq Biotechnology ETF

Senestech

Calidi Biotherapeutics

Kiniksa Pharmaceuticals

iTonic

SciSparc

Aditxt

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

A recent study revealed that there was a considerable enhancement in sleep quality among participants who underwent treatment using Nexalin’s stimulation approach of 15 milliamperes at 77.5 hertz. In contrast, the group receiving the sham treatment did not experience any notable improvements. This statistically significant difference indicates the superior effectiveness of Nexalin’s approach in improving sleep quality.

Unusual Whales

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects  and Clinical Improvement in Chronic Insomnia

Nexalin Technology, Inc. has partnered with Lindus Health to advance a pivotal clinical trial for its HALO Clarity device, aimed at treating moderate-to-severe insomnia. The trial will involve 160 participants and is designed to support a De Novo Classification Request to the FDA, with patient enrollment expected to start in Q2 2026. The global sleep tech devices market is projected to grow from $29.3 billion in 2025 to $153.7 billion by 2035. Nexalin's stock closed at $0.46, up 8.47%, but is down 1.70% in pre-market trading.

Nexalin Enters Agreement With Lindus Health To Advance Pivotal Clinical Trial Of HALO Clarity Device

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News

StockTitan

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News

Nexalin Tech(NXL.US)

Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial

Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary

Nexalin Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 14.95 K

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Nexalin Enters Agreement With Lindus Health To Advance Pivotal Clinical Trial Of HALO Clarity Device

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment | NXL Stock News